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A Scoping Review of Quality of
Life Questionnaires in Glaucoma Patients
Gus Gazzard, MA, MD, MBBChir, FRCOphth,*†
Miriam Kolko, MD, PhD,‡§ Michele Iester, MD, PhD,∥¶
David P. Crabb, MSc, PhD,#
On Behalf of the Educational Club of Ocular Surface
and Glaucoma (ECOS-G) Members
Precis: Multiple questionnaires exist to measure glaucoma’s impact on
quality of life (QoL). Selecting the right questionnaire for the research
question is essential, as is patients’ acceptability of the questionnaire to
enable collection of relevant patient-reported outcomes.
Purpose: QoL relating to a disease and its treatment is an important
dimension to capture. This scoping review sought to identify the
questionnaires most appropriate for capturing the impact of glau-
coma on QoL.
Methods: A literature search of QoL questionnaires used in glau-
coma, including patient-reported outcomes measures, was con-
ducted and the identified questionnaires were analyzed using a
developed quality criteria assessment.
Results: Forty-one QoL questionnaires were found which were ana-
lyzed with the detailed quality criteria assessment leading to a sum-
mary score. This identified the top 10 scoring QoL questionnaires rated
by a synthesis of the quality criteria grid, considering aspects such as
reliability and reproducibility, and the authors’ expert clinical opinion.
The results were ratified in consultation with an international panel of
ophthalmologists (N=49) from the Educational Club of Ocular Sur-
face and Glaucoma representing 23 countries.
Conclusions: Wide variability among questionnaires used to deter-
mine vision related QoL in glaucoma and in the responses elicited
was identified. In conclusion, no single existing QoL questionnaire
design is suitable for all purposes in glaucoma research, rather we
have identified the top 10 from which the questionnaire most
appropriate to the study objective may be selected. Development of
a new questionnaire that could better distinguish between treat-
ments in terms of vision and treatment-related QoL would be useful
that includes the patient perspective of treatment effects as well as
meeting requirements of regulatory and health authorities. Future
work could involve development of a formal weighting system with
which to comprehensively assess the quality of QoL questionnaires
used in glaucoma.
Key Words: glaucoma, patient-reported outcomes measure, quality
of life, questionnaire, treatment
(J Glaucoma 2021;30:732–743)
G laucoma is a group of chronic diseases that cause pro-gressive damage to the optic nerve and result in loss of
visual field. Primary open-angle glaucoma, which accounts for
three-quarters of all glaucoma cases, may be initially asymp-
tomatic and difficult to assess, but ultimately can result in
significant vision loss.1 The global prevalence of glaucoma
among people aged 40 to 80 years is 3.5%, with glaucoma
estimated to affect 76 million in 2020 and projected to reach
112 million by 2040.2 When lost, sight cannot be regained;
however, although blindness is a real risk, most people with
chronic glaucoma will not experience serious visual impair-
ment and will retain a good quality of life (QoL).3 Once loss
of visual field is at an advanced stage a tipping point is
reached at which loss of sight has significant impact on a
patient’s vision related QoL and psychological condition.4–6
Glaucoma negatively impacts on patients’ self-reporting of
visual functioning, mobility, independence, and emotional
wellbeing, particularly in those with late stage disease.
In ophthalmology, it has been acknowledged that tra-
ditional clinical measures such as high contrast visual acuity
do not reflect the patient’s experience or the impact of dis-
ease on patients’ lives.7 QoL measures may be the most
important overall assessments of treatment effect for
patients as they capture how their life experience is affected
by interventions. Outcomes including impact on dailyDOI: 10.1097/IJG.0000000000001889
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functioning, mobility, emotional wellbeing, and social
activities are of paramount concern for people being treated
for glaucoma. Measurement of QoL can be achieved using
patient-reported outcome measures (PROMs), which are
defined as: “any report of the status of patient’s health
condition that comes directly from the patient, without
interpretation of the patient’s response by a clinician or
anyone else.”8 PROMs are standardised, validated ques-
tionnaires, that are completed by patients to ascertain per-
ceptions of health status, perceived level of impairment,
disability, and QoL. PROMs allow for the systematic col-
lection of data relating to QoL and can be helpful for
monitoring health condition by assessing changes over time.
Ocular disease and its treatment can have adverse effects on
many aspects of a patient’s health including systemic side
effects, psychological, social, and emotional impact. Thus,
PROMs provide an instrument to understand the pro-
gression of ophthalmic disease and its overall impact on a
patient’s functional vision and QoL.
PROMs also offer a tool for audit or service evaluation
of glaucoma services, and for designing glaucoma trials.
PROMs are essential for clinical research and several deci-
sion makers, for example the Food and Drug Admin-
istration (FDA), mandate the assessment of PROMs in all
clinical trials and endorse the use of PROMs as primary
endpoints in glaucoma trials for new drug development.9
Consequently, PROMs are now often used as both primary
and secondary endpoints in ophthalmic clinical trials.10–12
PROMs provide a means for measuring treatment benefits
by capturing concepts related to how a patient feels or
functions with respect to his or her health or condition.8,9
The use of PROMs can allow a greater understanding of,
and sometimes improve, clinical outcomes. Nonetheless, in
clinical glaucoma research there is a need for well-validated
and easy to implement PROMs, as while numerous PROMs
have been used there is no gold standard in clinical use for
glaucoma.
In the 2017 clinical guidance for glaucoma, the
National Institute for Health and Care Excellence (NICE)
identified a research need for a new questionnaire to
measure QoL in patients with glaucoma, recognizing that
uncertainty exists as to which PROM should be used to
measure outcomes of glaucoma interventions [treatments
that aim to lower intraocular pressure (IOP), ie, a medi-
cation or surgical procedure].3 A suitable questionnaire
would be helpful to inform health care professionals and
policy makers about the effectiveness of glaucoma inter-
ventions on QoL benefit. To potentially achieve access to
new medicines, a previous evaluation by health author-
ities (regulators and health technology assessment bodies)
who need to be convinced of the clinical and QoL benefit
of such new medicines, is required. The identification of a
valid and responsive PROM in glaucoma would allow this
questionnaire to be adopted in future clinical trials and
glaucoma audits and would ensure meaningful compar-
isons between different interventions.3 This scoping
review sought to identify the questionnaires most appro-
priate for capturing the impact of glaucoma on QoL.
A secondary objective was to identify whether a difference
between glaucoma treatments in terms of impact on
QoL could be quantified using an available questionnaire.
To meet these objectives, a literature review and assess-
ment of all available questionnaires, including PROMs,
used to assess vision related QoL in glaucoma research
was conducted.
METHODS
The analysis was conducted in three parts. First, a lit-
erature search was performed to identify all relevant ques-
tionnaires, including PROMs, used to measure vision
related QoL in glaucoma and a quality analysis grid was
devised with which the instruments were analyzed. The top
10 questionnaires most applicable to glaucoma were deter-
mined by assimilating the results of the grid analyses and the
authors’ expert clinical opinion. These 10 questionnaires
were then further assessed by the wider group of experts of
the Educational Club of Ocular Surface and Glaucoma
(ECOS-G).
Part 1: Identification of Questionnaires
A bibliographic search in electronic databases includ-
ing PubMed and Embase (with an additional search on
Google Scholar) was performed to identify relevant pub-
lications from database inception up until April 2019. The
search terms used included, but were not limited to, glau-
coma, QoL, questionnaire, patient-reported outcomes
measure, treatment (see also the document, Supplemental
Digital Content 1, which contains full details of the search
methodology, http://links.lww.com/IJG/A560).
Eligible studies for inclusion involved people diagnosed
with glaucoma and ocular hypertension and were written in
English (other languages were excluded). However, the
questionnaire included could be written in another language
if at least one other publication about the questionnaire was
available in English (eg, Glau-QOL, Glausat). In addition,
studies had to consider the impact of glaucoma/ocular
hypertension/visual field loss on QoL using a QoL ques-
tionnaire or PROM. As most aspects of patient QoL were
considered, studies included did not necessarily have to
consider a glaucoma treatment effect (topical medication,
surgery, or laser treatment). Scales such as the Ocular Sur-
face Disease Index (OSDI), Oxford, Efron, and McMonnies
were excluded as their primary purpose is not to assess QoL,
rather they are standard instruments used to establish a
diagnosis of ocular surface disease. Other reasons for
exclusion included: only abstract published, studies not
including glaucoma or ocular hypertension patients, studies
carried out in very local regions or in a specific population
(ethnicity). We chose to focus on measuring QoL for the
population with primary open-angle glaucoma with the
exclusion of all secondary glaucomas, which often exhibit
more rapid change and greater vision loss.
Part 2: Qualitative and Quantitative Analysis
Round 1
To assess the questionnaires used to measure QoL in
glaucoma patients, an evaluation grid of quality criteria
with a rating scale was developed (see the document, Sup-
plemental Digital Content 2, which contains the quality
criteria grid template, http://links.lww.com/IJG/A561). The
grid design was based on the literature and the authors’
expertise when interviewing their patients (Table 1).13–25
Some studies have already thoroughly assessed meas-
urement properties of QoL questionnaires and have
proposed lists of key quality criteria to address. All these
studies and works were used as a guide to create the quality
grid analysis. For example, The Scientific Advisory
Committee of the Medical Outcomes Trust made review
criteria which addressed 8 attributes or characteristics of an
instrument:21,26
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 Respondent and administrative burden
 Cultural and language adaptations
The COSMIN (COnsensus-based Standards for the
selection of health status Measurement INstruments) study
reached international consensus on definitions of measure-
ment properties for health-related PROMs.22 This checklist
was also used to implement our grid analysis. The COSMIN
checklist normally consists of 9 boxes divided over 3
domains (reliability, validity, and responsiveness), with
methodological standards for how each measurement













Reliability is defined as the extent to which scores for
patients who have not change are the same for repeated
measurement under several conditions. Responsiveness is
defined as the ability of an instrument to detect change over
time in the construct to be measured.22 Validity is the extent
to which scores on instruments are an adequate reflection of
a gold standard and are consistent with hypothesis. Multiple
types of test validity were incorporated into the grid analysis
(Supplemental Digital Content 2, http://links.lww.com/IJG/
A561) to determine the accuracy of the components of a
measure, including:25
 Content validity—the extent to which the content meets
the prestudy hypothesis specifications
 Criterion validity—the extent to which scores on instru-
ments are an adequate reflection of a gold standard
 Construct validity—the extent to which scores of an
instrument are consistent with hypothesis, based on
existing knowledge about the construct
 Structural validity—the degree to which the scores of an
instrument are an adequate reflection of the (uni)
dimensionality of the construct to be measured using
factor analysis to confirm the number of subscales present
in a questionnaire
 Cross-cultural validity—the degree to which the perform-
ance of the items on a translated or culturally adapted
instrument is an adequate reflection of the performance
of the items of the original version of the instrument
The final grid analysis resulted in 3 main domains
(instrument description, instrument development, and psycho-
metric evaluation) of quality criteria including assessments in the
areas detailed in Table 2.22 Note that a description of each item
and methodological standards for how each item should be
assessed were detailed in the grid for the appraiser who eval-
uated the questionnaire (see the document, Supplemental Dig-
ital Content 2, for this information which is contained in the
quality criteria grid template, http://links.lww.com/IJG/A561).
From the completed quality criteria grid for the 41
QoL questionnaires, a further quantitative assessment was
TABLE 1. Summary of the Process Adopted to Create the Quality Criteria Analysis Grid
Step 1 Identifying existing scoring of QoL questionnaires (including PROMs) in primary publications and review articles found during the
literature review and thus related to glaucoma,13–20 and other publications appraising the quality of the QoL questionnaire against
set criteria21–25
Step 2 Indexing all the parameters used to assess a QoL questionnaires
Step 3 Comparing with parameters used to assess each of the QoL questionnaires in the publications included: add missing ones and
remove duplicates
Step 4 Identifying common ‘themes’ among all parameters
Step 5 Synthesizing findings in a table with a 4-point scoring scale:
++ high; + medium; – low; 0 not reported
Step 6 Validating results with a panel of experts
PROM indicates patient-reported outcomes measure; QoL, quality of life.
TABLE 2. Quality Criteria Analysis Grid Domains and Parameters Assessed for Each Quality of Life Questionnaire
Domains Parameters Assessed
Instrument description Concept, general, vision or glaucoma-specific, number of items, rating scale, interpretation score, mode of
administration, effort to respond
Instrument development Prestudy hypothesis, content validity, item selection, unidimensionality, item fit statistics (Rasch model), response
scale, scoring
Psychometric evaluation Criterion validity: the extent to which scores on instruments are an adequate reflection of a gold standard22
Construct validity: the extent to which scores of an instrument are consistent with hypothesis, based on existing
knowledge about the construct
Reliability: the extent to which scores for patients who have not change are the same for repeated measurement
under several conditions
For each appropriate quality parameter, a score was assigned as follows:
++ high; + medium; – low; 0 not reported
Gazzard et al J Glaucoma  Volume 30, Number 8, August 2021
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made by applying a score to the 28 qualities assessed in
parts II and III (part II: instrument development and part
III: psychometric properties). Note that part I contains
qualitative descriptive parameters only that cannot be
scored. The 4-point rating scale: ++ high; + medium; –
low; 0 not reported was converted to a numerical scoring
value as follows: ++= 2, += 1, –= –1 and 0= 0, allowing
for a maximum total score of 52 (as not every parameter
had an available score of 2, eg, measurement error was
rated from –1 to 1; see Supplemental Digital Content 2 for
rating guidance, http://links.lww.com/IJG/A561).
Part 3: Qualitative Analysis Round 2
For the second-round analysis by the ECOS-G
experts of the top 10 scoring identified QoL ques-
tionnaires, a panel of international ophthalmologists from
23 countries, a simplified evaluation grid was developed
(see Table 3) including 8 quality parameters and using the
same 4-point scoring scale: ++ high; + medium; – low; 0
not reported.
RESULTS
Part 1: Identification of Questionnaires
The study selection process is outlined in Figure 1
(Flowchart). Ultimately, 64 publications and 7 reviews (71
publications) were identified from the literature relating to
41 different QoL questionnaires (general health, vision-
specific and glaucoma-specific questionnaires) which were
included in the qualitative analysis (see Table, Supple-
mental Digital Content 3, which lists the 41 QoL ques-
tionnaires included in the analysis, http://links.lww.com/
IJG/A562).15,28–81
Part 2: Qualitative and Quantitative Analysis
Round 1
Quality appraisal was conducted on 41 questionnaires
using the quality criteria grid (see the document, Supple-
mental Digital Content 2, which contains the quality cri-
teria grid template, http://links.lww.com/IJG/A561). From
the detailed qualitative analysis of the 41 QoL ques-
tionnaires provided by completion of the quality criteria
grid, a further quantitative assessment was made by cal-
culating a total score for each of the 41 QoL questionnaires
as presented in the Supplementary Digital Content 4
(http://links.lww.com/IJG/A563). The score reflected a
trade-off between the psychometric properties, the number
and frequency of citations in the literature, the simplicity of
the language used, length of the items, time taken to
complete the questionnaire, whether the questionnaire is
widely translated, etc., which was all captured within the
quality criteria grid.
From assessment of the 41 questionnaires, the top
scoring 12 questionnaires were reviewed by the authors and
the top 10 performing questionnaires agreed upon by con-
sensus after discussion. Both the Glausat and SHPC ques-
tionnaires scored highly (within the top 10) but were not
taken forward as either were not provided in English or only
supported by a low level of evidence and so were considered
not widely applicable (Supplementary Digital Content 4,
http://links.lww.com/IJG/A563). A further qualitative
assessment of the top 10 questionnaires is provided in
Table 4 as a summary of advantages and disadvantages for
each questionnaire identified from a synthesis of reports in
the literature and from views provided by the 4 authors. The
results of the literature survey and top 10 questionnaire
selection were submitted to a panel of international experts
(ECOS-G) for a second round of review and validation.
TABLE 3. Simplified Quality Criteria Analysis Grid for Assessing Quality of Life Questionnaires Used in Glaucoma
Quality Parameters Guidance
Circle Your Response and Justify
if Needed*
1. Prestudy hypothesis Is the rational of the questionnaire explained (here or in former
publications)?
++ + – 0
2. Intended population Are glaucoma patients involved? ++ + – 0
If no, what is the other population?___________________
Is this studied/intended population relevant vs. glaucoma patients?
3. Item identification and
selection




++ + – 0
Was the pilot questionnaire tested (rash or factor analysis, statistical
justification of final items)?
Are the items clinically relevant to the target population?
4. Scoring Is there a description of the different parameters and of how the
questionnaire should be scored?
++ + – 0
5. Validity Was the questionnaire previously compared with another (or other
measurements)?
++ + – 0
If yes, did the questionnaire correlate with scores of the other
questionnaire/measurements?
6. Sensitivity Is the questionnaire able to discriminate? ++ + – 0
A glaucoma patient from a nonglaucoma patient?
Different stages and severity of the disease?
7. Responsiveness Is the questionnaire able to detect clinical changes and trends over
time?
++ + – 0
8. Ease of use Is the questionnaire easy to administer/fill-in for the patient? (training
needed, time to fill-in, clear items, etc.)
++ + – 0
*Assessment using a 4-point scoring scale: ++ high; + medium; – low; 0 not reported.
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Part 3: Qualitative Analysis Round 2
The top 10 questionnaires assessing vision related QoL
for glaucoma patients were further assessed by the ECOS-G
experts. The results of the second-round assessment using a
simplified quality grid analysis validated the first-round
results and are presented in Table 5.
DISCUSSION
From a review of the literature and evaluation of the
array of questionnaires and PROMs used in glaucoma to
assess QoL, the top 10 questionnaires most appropriate for
use in QoL-related research in glaucoma were identified by
the synthesis of a literature search and the authors’ expert
opinion (Table 4). The findings on the advantages and dis-
advantages of these questionnaires were a synthesis of lit-
erature reports and personal experience of the authors and
are largely in agreement with earlier reviews.14,16,18,20,28,44
Each of the questionnaires selected is unique and presents
interesting and useful parameters. Questionnaires and
PROMs used to assess QoL in glaucoma are diverse and not
all are disease specific; the 10 that we identified include the
best glaucoma specific, vision specific, treatment specific,
and general health questionnaires currently available. While
this assessment identified glaucoma-specific scales to be
most appropriate in the main for identifying disease-related
impact on health, some vision-specific (NEIVFQ-25) and
general health (MOS SF-36) questionnaires were also iden-
tified that are appropriate for gathering holistic information,
such as social and psychological dimensions. For the sec-
ondary study objective, the TSS-IOP and COMTol scales
may be the most appropriate for determining differences
between 2 treatments in terms of factors affecting QoL.
The questionnaires available are often complex with
multidimensional scales that differ in the categories of
assessments included. Consequently, it can be very difficult
to comparatively assess the questionnaires as there are many
parameters involved, and not all are assessing the same
aspects of glaucoma care, for example, some are more
focused on the impact on daily activities, others on disease
progression, while others on patient satisfaction. None of
the questionnaires scored well across all set criteria in this
analysis (in the simplified grid, Table 5). The scales identi-
fied also vary in the level of validation and sensitivity to
measure appropriate outcomes. None capture all relevant
information, so selection of a scale is a trade-off based upon
the most important factors under investigation.
Generally, currently available questionnaires are not
sufficiently sensitive to monitor changes in QoL over time,
especially in patients at early stages of glaucoma. Moreover,
differences in scores for patients with stable or progressing
glaucoma may only be evident on some questionnaires and
not others. However, if QoL questionnaires are to be used to
shape policy, secure funding, and manage patients, to be
effective, they must be sensitive to disease progression. In
this regard, the glaucoma-specific Glau-QoL 36, and the
shorter versions GQL-15 and GAL-9 may be the best tools
to detect deterioration in QoL correlating with disease
progression, and for identifying differences between patients
who have progressed and those who have not.11 GQL-15 is
reliable in assessment of mild, moderate, and severe glau-
coma, and may be the most clinically relevant tool.16,44 The
FIGURE 1. Study selection process. †Explanation provided in methods section part 1. OHT indicates ocular hypertension; OSDI, Ocular
Surface Disease Index; QoL, quality of life.
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GAL-9 (GAL-10) may also offer advantages as a high-
quality questionnaire for assessing activity limitation and
mobility that can be completed in a relatively short time.18
The Viswanathan questionnaire is also able to detect sig-
nificant differences between patients with mild, moderate,
and severe glaucoma in terms of visual disability and cor-
relates well with visual field indices.28,80 In comparison, the
Symptom Impact Glaucoma Score (SIG) is a questionnaire
containing 43 items that is responsive to treatment effects
and disease severity, but may be most appropriately used in
research because of its length.16,20 The AGQ was designed
to evaluate the effectiveness of glaucoma screening com-
pared with no formal screening (opportunistic case detec-
tion) in a randomised clinical trial.70 It was shown to
discriminate between people without glaucoma and those
with significant disease in a hospital-based sample
population.71 However, while a promising questionnaire, it
is lengthy (31 items) and requires further validation, so may
be best suited to research purposes at this time.
For a general-heath perspective, the MOS SF-36 although
not found to correlate well with visual field indices does offer an
assessment of the patient’s general health and wellbeing by
capturing both physical and mental health status and requires
on average less than 10 minutes to complete.28,81,82 The
NEIVFQ-25 also provides additional information regarding
the general, psychological, and social effects of glaucoma and
has high content validity.20,44,78 It is worth highlighting that our
review did not directly consider performance-based measures
where tasks are used to measure functional performance.83–85
Such approaches have been shown to be psychometrically valid
and could be useful along with hybrid methods that try to
capture a measure of a person’s so-called patient-reported
outcome and experience (POEM).86
Other questionnaires such as the Glaucoma Satisfaction
Questionnaire (Glausat) and the Symptom Health Problem
Checklist (SHPC) were identified as interesting options and
were thoroughly considered but were subsequently excluded
from the top 10 questionnaires because of either a lack of
evidence or no availability in English language. The SHCP,
an 18-item version of the SIG [which consisted of 43 items,
4-domain tool, in the Collaborative Initial Glaucoma
Treatment Study (CIGTS)] proposed by Musch et al,68 was
able to differentiate between disease severity on local eye and
visual function (P< 0.05) and that patients who underwent
trabeculectomy reported higher frequency of local eye
symptoms than those with topical medications (P< 0.01).
However, it should be tested in other clinical settings to
demonstrate its general applicability. In a study using the
Glausat,72 a 22-item Spanish questionnaire containing 7
dimensions (expectations and beliefs about treatment, ease of
use, efficacy, undesired effects, impact on health-related
QoL, medical care, general satisfaction with treatment), the
authors demonstrated that the questionnaire is reliable and
structurally valid. No information is currently available on
the stability of this questionnaire over time, sensitivity to
change, ability to discriminate between pathologic groups, or
concurrent validity with other alternative measures.
Although there is now a requirement to collect QoL data in
studies, the recommendations of which questionnaire should be
used in clinical trials remain unclear and the ones currently
recognized by health authorities may not be relevant depending
on the aim of the study.87 QoL questionnaires may offer value
when 2 interventions have been established to be equally effi-
cacious in terms of a traditional outcome measure (eg, IOP-
lowering effect), but where differences are anticipated in terms of
side effects, cost, or convenience. However, while questionnaires
may have a very useful role in practice for reflecting patient
perspectives, evidence suggests QoL questionnaires lack sensi-
tivity at distinguishing between treatment groups or even versus
placebo.11 Nonetheless, QoL is a requirement of regulatory and
health authorities when assessing the benefit of new treatments.
QoL assessment is mandated by the FDA and the French health
technology assessment body (Haute Autorité de Santé; HAS) for
chronic diseases.8,87 The US FDA endorses the use of QoL
questionnaires (including PROMs) as primary endpoints in
glaucoma trials, but also recognizes the challenges in developing
appropriate questionnaires.9,88 The HAS requires QoL data to
be collected in double-blinded studies, including detailed
methodology with validated questionnaires and scales and clin-
ically relevant criteria in the study population of interest.87 Our
analysis has identified the 2 questionnaires TSS-IOP and
COMTol that among the questionnaires currently available may
be the most appropriate to reach health authorities’ expectations
of determining differences between 2 treatments in terms of
factors affecting QoL. The TSS-IOP may be the highest quality
tool for measuring topical treatment side effects.14,17 It is
designed to assess patient satisfaction with topical ocular medi-
cations used to control IOP and has high content validity across
eye drop classes.20 In comparison with COMTol, the TSS-IOP
used a higher quality developmental process for identifying and
selecting items and has better validity evidence. COMTol is
designed to capture the frequency and “bothersomeness” of
common side effects of topical therapy for lowering IOP and the
extent to which these side effects impact on QoL.20 COMTol has
been tested and used in the framework of a crossover design and
can be adapted for other study comparative designs. It is also
designed for comparison of topical medicines only; did not detect
a difference between eye drops and selective laser trabeculoplasty
in one study.52 Nonetheless, it is a questionnaire recognized by
the HAS for capturing QoL data in clinical trials.
It is a limitation of our study that a formal weighting system
is not available with which to comprehensively assess the quality
of QoL questionnaires used in glaucoma. As the process under-
taken for our assessment was very detailed, and thus time con-
suming, one limitation of the study is that because of resource
constraints not all questionnaires were screened by all experts.
The top scoring 12 questionnaires were reviewed by the authors
and the top 10 performing questionnaires agreed upon by con-
sensus after discussion. In our opinion, the 10 selected most
broadly represent QoL questionnaires ideally suited to measure
aspects of QoL associated with glaucoma treatment. As this was
a Scoping review, future work could entail a more detailed
assessment of QoL questionnaires including development of a
formal weighting system with which to comprehensively assess
the quality of QoL questionnaires used in glaucoma.
In summary, wide variability in the questionnaires used
to determine QoL in glaucoma and in the responses elicited
was identified. No single existing QoL questionnaire design
is suitable for all purposes in glaucoma research, rather we
have identified the top 10 from which the questionnaire most
appropriate to the study objective may be selected. Devel-
opment of a new questionnaire that could better distinguish
between treatments in terms of vision and treatment-related
QoL would be useful that includes the patient perspective of
treatment effects as well as meeting requirements of regu-
latory and health authorities. The desirable attributes of a
new glaucoma-specific QoL questionnaire would include
ease of use (short, self-administered, simplicity of language),
with an easily understandable scoring system and high
reliability and reproducibility, sensitivity, and validity. The
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TABLE 4. The Top 10 Questionnaires Identified as Appropriate for Use in Vision Related Quality of Life Research in Glaucoma: Advantages and Disadvantages





Design: to measure patient health
Domains: physical activities, social activities, usual role
activities, bodily pain, general mental health,
emotional, vitality, general health
Number of items: 36
Effort to complete: Low
Time to administer: Average 8 min82
Good correlation with age28
Recognized by the HAS for adding QoL data in
clinical trials
Weak correlation between SF-36
scores and visual field indices






Design: to measure QoL
Domains: general health, general vision, mental health,
ocular pain, near vision, distance vision, peripheral
vision, social function, color vision, driving, role
limitation, dependency
Number of items: 25
Effort to respond: Low
Time to administer: Average 14min44
Gives information regarding the general,
psychological, and social effects of glaucoma
Recognized by the HAS for adding QoL data in
clinical trials
Lack of visual field consideration is a
limitation in comparison to specific
glaucoma tools16
Glaucoma Quality of Life-
36 (Glau-QoL 36)65,79
Focus: Glaucoma-specific
Design: to assess problems encountered on a daily basis
because of glaucoma vision and treatment, and impact
on everyday life
Domains: psychological wellbeing, self-image, daily life,
burden of treatment, driving, anxiety, and confidence
in health care
Number of items: 36
Effort to respond: High
Time to administer: NA
Excellent correlations with disease progression
Tested on 800 patients
Only tool to have both tested convergent and
discriminant validity
Detects QoL effects in patients who do not have
problems in functioning (unlike other
questionnaires)
Overall QoL assessment
French, English, Polish, and Indian languages
Shorter 17-item version convenient for patients79
Recognized by the HAS for adding QoL data in
clinical trials
Cannot differentiate between 2
treatments regarding satisfaction,
compliance, ease of use, etc.
Focus is on psychological wellbeing
regarding glaucoma
Long
Does it have any advantage over the
GQL-15/GAL-9 which are shorter?
Glaucoma Quality of Life
(GQL-15)52,66,67
Focus: Glaucoma-specific
Design: to measure the effect of binocular visual field
loss on functional vision
Domains: outdoor mobility, peripheral vision, near
vision, glare/dark adaptation
Number of items: 15
Effort to respond: Low
Time to administer: Average 7 min44
Detects association of decreased vision with
glaucoma–good to assess disease progression
Differentiates different stages of the disease even
between mild and moderate in some cases67
Good psychometric properties
Very known and widely used in studies
Tested with Rash-analysis
Considered as the most useful and clinically
relevant tool16
User-friendly in clinical practice
Recognized by the HAS for adding QoL data in
clinical trials
Good reliability
Does not capture scope or burden of
symptoms and broad QoL factors
Only functional status measurement
Does not take side effects into account
No difference between treatment and
placebo11 (same for GAL-9)
Not recommended by Khadka et al
2013 because it violates the
condition of unidimensionality18
Shorter version GAL-9/10 is available
which is a higher quality instrument


















































Design: to measure vision related activity limitations
(Rasch analyzed version of GQL-15)
Domains: outdoor mobility, peripheral vision, near
vision, glare/dark adaptation
Number of items: 9
Effort to respond: Low
Time to administer: NA
Short version GAL-9 (GAL-10 in India): higher
quality than GQL-15 for assessing activity
limitation and mobility18
GAL-9 is quicker to administer than GQL-15 and
has same properties as the 15 questions
Highly cited69
Has similar properties in determining differences






Design: to evaluate the effectiveness of glaucoma
screening compared with no formal screening
(opportunistic case detection)
Domains: participation, moving around and
communication, emotional function, walking around
obstacles, light, domestic and social life, mobility
Number of items: 68 (31 items in revised AGQ)
Effort to respond: High
Time to complete: NA
Able to discriminate between people without
glaucoma and those with significant disease71
Uses the ICF as a theoretical framework to code
the AGQ item content by identifying
meaningful concepts (ie, ideas or information)
contained within each AGQ item and linking
each meaningful concept to the most precise
ICF category
Provides a robust method for linking the empirical
factors with a theoretical factor structure and
for assigning theoretically informed labels
during early testing of new PROM instruments
using Classical Test Theory techniques
Pre-validation development was conducted in a
previous study70
NEIVFQ-25 was included as a benchmark to
assess the AGQ
Items are clear
Promising instrument and method
Scoring method to be further
investigated: the use of scores for
identifying individual-level severity
would not be appropriate
Further testing (eg, Rasch analysis)
should be conducted to provide
greater insight into the psychometric
properties and dimensionality of the
AGQ
As far as we know, it has not been
used in other studies





Design: to measure visual disability
Domains: quality of vision, ability to perform activities
Number of items: 10
Effort to respond: Low
Time to administer: Average 5 min44
High internal consistency (Cronbach’s α= 0.929)44
Statistically significant difference between patients
with mild, moderate, and severe glaucoma
detected (P≤ 0.001)44
Simple and fast to administer
Good correlation with NEIVFQ-25 and GQL-15,
especially for peripheral vision and glare/dark
adaptation44





Design: to measure frequency of symptoms related to the
disease and/or side effects of treatments, and
bothersomeness
Domains: visual function, local eye symptoms, systemic
symptoms
Number of items: 43 (4 domains)
Effort to respond: High
Time to complete: NA
Captures local eye and visual function symptoms
of glaucoma and its treatment
Responsive to treatment effects and disease
severity
Consistent, statistically significant correlation with
NEIVFQ-25
Good responsiveness (longitudinal psychometric
assessment)
Long-term follow-up (54 mo)
Large sample of patients (607 at baseline and 510
at 54 mo)
Does not take side effects into account
All questions relate to eye/vision
symptoms
No questions to assess systemic side
effects
Items relating to eye symptoms do not
necessarily cover all glaucoma
treatment side effects, such as skin/
eyelash pigmentation























































Instrument Description Advantages Disadvantages
Considered as an excellent research tool16,20
Part of the exam set-up by the CIGTS reference








Design: to capture the frequency and bother of common
side effects of topical therapy for lowering IOP. Also
measures the extent to which these side effects and any
associated limitations in routine living activities
interfere with QoL, medication compliance, and
patient satisfaction
Domains: Symptom frequency, bothersomeness, activity
limitations, global QoL, satisfaction, adherence
Number of items: 37 items (13 domains)
Effort to respond: Low–Moderate
Time to complete: NA
Influence of glaucoma therapy on QoL
considering frequency and severity of common
side effects
Good assessment by Che Hamzah et al20
Good psychometric properties
Strong correlation between frequency, bother and
patient-perceived measures
Responsiveness to change
Tested and used in the framework of a crossover
design
Demonstrated sharp improvement after a switch
from bimatoprost-timolol to tafluprost-timolol
for almost all symptoms and limitations (no
statistical analyses were performed)77
Recognized by the HAS for adding QoL data in
clinical trials
Designed for topical medication only
(not surgery/laser) (no difference eye
drops vs. SLT in Lee et al)52
Only differentiation between timolol
and pilocarpine so far
Should be adapted if no crossover
design
No patient knowledge and perception
of treatment
Very lengthy and likely to be
burdensome to complete. This
would also incur greater costs





Design: to assess patient satisfaction with topical ocular
medications to control IOP
Domains: effectiveness, side effects, eye appearance,
convenience of use, ease of administration
Number of items: 15
(+27 supplemental items)
Effort to respond: Low
Time to administer: NA
Investigates side effects because of topical
medication:
Patient knowledge and perception of treatment
Validation on a large sample of patients
Derived from a generic questionnaire (IQVIA’s
Treatment Satisfaction Questionnaire for
Medication [TSQM])
Shows acceptable reliability and good validity
across all eye drop classes
Compared with COMTol: higher quality
developmental process in view of identifying
and selecting items and better validity evidence
Covers relevant side effects and issues with eye
appearance, which might relate to patients
Considered by:
Vandenbroeck et al14 2001 as the highest quality
tool for measuring topical treatment side effects
Hamzah et al20 as having the highest content
validity
Quaranta et al17 as the instrument of choice for
comparing different classes of topical
medication
Only performed on available patients
that were already scheduled for
clinic
Focus is on satisfaction regarding
treatment, no data on efficacy of the
treatment or progression of the
disease
Does not assess visual problems per se
CIGTS indicates Collaborative Initial Glaucoma Treatment Study; HAS, Haute Autorité de Santé (French health technology assessment body); ICF, International Classification of Functioning and Disability; IOP,













































mode of administration may influence patient responses and
is worth considering. Self-administered questionnaires
(PROMs) are to be preferred, while a lengthy questionnaire,
complex language, or distorted adaptations because of
translation issues can be burdensome for the patient. The
effort required to provide a full response to the ques-
tionnaire and the time taken to complete are important to
consider when making the questionnaire patient friendly. To
be effective, the questionnaire needs to be understandable to
its respondents. A recent study determined that over half of
questionnaires commonly used in ophthalmology require a
reading comprehension level better than that recommended
by the American Medical Association (AMA) and National
Institutes of Health (NIH) as appropriate for patient
materials.89 In future, item banking and computerized
adaptive testing methods may address the multiple limi-
tations of paper-pencil questionnaires, customize their
administration, and have the potential to improve health
care outcomes for patients with glaucoma.90 The collection
of patient-reported QoL data will enable better under-
standing of vision related QoL that can improve patient–
physician interaction and enhance treatment adherence by
providing patient-centric care that can ultimately optimize
the long-term prognosis for glaucoma patients.
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